Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities

Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities

Background Heterologous oncolytic virus prime-boost vaccination is emerging as a promising cancer immunotherapy to establish potent antitumor immunity. With their natural ability to specifically destroy cancer cells, oncolytic viruses also allow for direct oncolysis and our team has previously demon...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie-Claude Bourgeois-Daigneault, Victor Mullins-Dansereau, Marie-Lou Myre, Angelina Bardoul, Karen Geoffroy, Marco J Rallo Pita, Delphine Béland, Kim Leclerc Desaulniers, Dominic Guy Roy
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e010570.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items